TIPS versus endoscopic therapy for variceal rebleeding in cirrhosis: A meta-analysis update

Abstract

Endoscopic therapy (ET) is most common method for preventing variceal bleeding in cirrhosis, but the outcomes are not perfect. Recently, transjugular intrahepatic portosystemic shunt (TIPS) is introduced into clinical practice. However, the beneficial effects of TIPS compared to ET on cirrhotic patients is unknown. The aim of this study was to evaluate and compare the effects of TIPS with those of the most frequently used ET for prevention of variceal rebleeding (VRB) in liver cirrhosis. The Pub-Med, EMBASE, and Cochrane Library databases were searched from inception to February 2017. The primary study outcomes included the incidence of VRB, all-cause mortality, bleeding-related death, and the incidence of post-treatment hepatic encephalopathy (PTE). The odds ratios (ORs) with 95% confidence intervals (CI) were pooled for dichotomous variables. Subgroup analyses were performed. Twenty-four studies were eligible and they included 1120 subjects treated with TIPS and 1065 subjects treated with ET. Although there was no significant difference in survival and PTE, TIPS was superior to ET in decreasing the incidence of VRB (OR=0.27; 95% CI, 0.19–0.39, P<0.00001), and decreasing the incidence of bleeding-related death (OR=0.21; 95% CI, 0.13–0.32, P<0.00001). Subgroup analysis found a lower mortality (OR=0.48; 95% CI, 0.23–0.97; P=0.04) without any increased incidence of PTE (OR=1.37; 95% CI, 0.75–2.50; P=0.31) in the studies of a greater proportion (≥40%) of patients with Child-Pugh class C cirrhosis receiving TIPS, and TIPS with covered stent did not increase the risk of PTE compared to ET (OR=1.52, 95% CI =0.82–2.80, P=0.18). It was concluded that TIPS with covered stent might be considered the preferred choice of therapy in patients with severe liver disease for secondary prophylaxis.

Keywords

transjugular intrahepatic portosystemic shunt / endoscopic therapy / variceal bleeding / cirrhosis / meta-analysis

References

[1] de FranchisR, BavenoVF. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol, 2010, 53(4): 762-768 PMID: 20638742

[2] RossleM. TIPS: 25 years later. J Hepatol, 2013, 59(5): 1081-1093 PMID: 23811307

[3] BoyerTD, HaskalZJAmerican Association for the Study of Liver D. The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension. Hepatology, 2005, 41(2): 386-400 PMID: 15660434

[4] Garcia-TsaoG, SanyalAJ, GraceND, et al. . Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology, 2007, 46(3): 922-938 PMID: 17879356

[5] BanaresR, AlbillosA, RinconD, et al. . Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: a meta-analysis. Hepatology, 2002, 35(3): 609-615 PMID: 11870374

[6] WellsGA, SheaB, O’ConnellD, et al. . The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses, 2013

[7] CabreraJ, MaynarM, GranadosR, et al. . Transjugular intrahepatic portosystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology, 1996, 110(3): 832-839 PMID: 8608893

[8] CelloJP, RingEJ, OlcottEW, et al. . Endoscopic sclerotherapy compared with percutaneous transjugular intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal hemorrhage. A randomized, controlled trial. Ann Intern Med, 1997, 126(11): 858-865 PMID: 9163286

[9] JalanR, ForrestEH, StanleyAJ, et al. . A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. Hepatology, 1997, 26(5): 1115-1122 PMID: 9362350

[10] RossleM, DeibertP, HaagK, et al. . Randomised trial of transjugular-intrahepatic-portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding. Lancet, 1997, 349(9058): 1043-1049 PMID: 9107241

[11] SanyalAJ, FreedmanAM, LuketicVA, et al. . Transjugular intrahepatic portosystemic shunts compared with endoscopic sclerotherapy for the prevention of recurrent variceal hemorrhage. A randomized, controlled trial. Ann Intern Med, 1997, 126(11): 849-857 PMID: 9163285

[12] SauerP, TheilmannL, StremmelW, et al. . Transjugular intrahepatic portosystemic stent shunt versus sclerotherapy plus propranolol for variceal rebleeding. Gastroenterology, 1997, 113(5): 1623-1631 PMID: 9352865

[13] MerliM, SalernoF, RiggioO, et al. . Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal bleeding in cirrhosis: a randomized multicenter trial. Gruppo Italiano Studio TIPS (G.I.S.T.). Hepatology, 1998, 27(1): 48-53 PMID: 9425916

[14] Garcia-VillarrealL, Martinez-LagaresF, SierraA, et al. . Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal rebleeding after recent variceal hemorrhage. Hepatology, 1999, 29(1): 27-32 PMID: 9862845

[15] NaraharaY, KanazawaH, KawamataH, et al. . A randomized clinical trial comparing transjugular intrahepatic portosystemic shunt with endoscopic sclerotherapy in the long-term management of patients with cirrhosis after recent variceal hemorrhage. Hepatol Res, 2001, 21(3): 189-198 PMID: 11673103

[16] Pomier-LayrarguesG, VilleneuveJP, DeschenesM, et al. . Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial. Gut, 2001, 48(3): 390-396 PMID: 11171831 PMCID: 1760139

[17] GülbergV, SchepkeM, GeigenbergerG, et al. . Transjugular intrahepatic portosystemic shunting is not superior to endoscopic variceal band ligation for prevention of variceal rebleeding in cirrhotic patients: a randomized, controlledtrial. Scand J Gastroenterol, 2002, 37(3): 338-343 PMID: 11916197

[18] SauerP, HansmannJ, RichterGM, et al. . Endoscopic variceal ligation plus propranolol vs. transjugular intrahepatic portosystemic stent shunt: a long-term randomized trial. Endoscopy, 2002, 34(9): 690-697 PMID: 12195325

[19] LoGH, LiangHL, ChenWC, et al. . A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy, 2007, 39(8): 679-685 PMID: 17661241

[20] ProcacciniNJ, Al-OsaimiAM, NorthupP, et al. . Endoscopic cyanoacrylate versus transjugular intrahepatic portosystemic shunt for gastric variceal bleeding: a single-center U.S. analysis. GastroIntest Endosc, 2009, 70(5): 881-887 PMID: 19559425

[21] Garcia-PaganJC, CacaK, BureauC, et al. . Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med, 2010, 362(25): 2370-2379 PMID: 20573925

[22] PopovicP, StabucB, SkokP, et al. . Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy in the elective treatment of recurrent variceal bleeding. J Int Med Res, 2010, 38(3): 1121-1133 PMID: 20819451

[23] XueH, ZhangM, PangJX, et al. . Transjugular intrahepatic portosystemic shunt vs endoscopic therapy in preventing variceal rebleeding. World J Gastroenterol, 2012, 18(48): 7341-7347 PMID: 23326143 PMCID: 3544040

[24] Garcia-PaganJC, Di PascoliM, CacaK, et al. . Use of early-TIPS for high-risk variceal bleeding: results of a post-RCT surveillance study. J Hepatol, 2013, 58(1): 45-50 PMID: 22940408

[25] HolsterIL, TjwaETTL, MoelkerA, et al. . Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + beta-blocker for prevention of variceal rebleeding. Hepatology, 2016, 63(2): 581-589 PMID: 26517576

[26] KochharGS, NavaneethanU, HartmanJ, et al. . Comparative study of endoscopy vs. transjugular intrahepatic portosystemic shunt in the management of gastric variceal bleeding. Gastroenterol Rep (Oxf), 2015, 3(1): 75-82

[27] RudlerM, CluzelP, CorvecTL, et al. . Early-TIPSS placement prevents rebleeding in high-risk patients with variceal bleeding, without improving survival. Aliment Pharmacol Ther, 2014, 40(9): 1074-1080 PMID: 25230051

[28] MonescilloA, Martinez-LagaresF, Ruiz-del-ArbolL, et al. . Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding. Hepatology, 2004, 40(4): 793-801 PMID: 15382120

[29] SauerbruchT, MengelM, DollingerM, et al. . Prevention of rebleeding from esophageal varices in patients with cirrhosis receiving small-diameter stents versus hemodynamically controlled medical therapy. Gastroenterology, 2015, 149(3): 660-668 PMID: 25989386

[30] JalanR, BzeiziKI, TripathiD, et al. . Impact of transjugular intrahepatic portosystemic stent-shunt for secondary prophylaxis of oesophageal variceal haemorrhage: a single-centre study over an 11-year period. Eur J Gastroenterol Hepatol, 2002, 14(6): 615-626 PMID: 12072595

[31] ZhengM, ChenY, BaiJ, et al. . Transjugular intrahepatic portosystemic shunt versus endoscopic therapy in the secondary prophylaxis of variceal rebleeding in cirrhotic patients: meta-analysis update. J Clin Gastroenterol, 2008, 42(5): 507-516 PMID: 18344888

[32] SalernoF, CammaC, EneaM, et al. . Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology, 2007, 133(3): 825-834 PMID: 17678653

[33] CasadabanLC, ParvinianA, MinochaJ, et al. . Clearing the confusion over hepatic encephalopathy after TIPS creation: Incidence, prognostic factors, and clinical outcomes. Dig Dis Sci, 2015, 60(4): 1059-1066 PMID: 25316553

[34] PerarnauJM, Le GugeA, NicolasC, et al. . Covered vs. uncovered stents for transjugular intrahepatic portosystemic shunt: a randomized controlled trial. J Hepatol, 2014, 60(5): 962-968 PMID: 24480619

[35] YangZ, HanG, WuQ, et al. . Patency and clinical outcomes of transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stents versus bare stents: a meta-analysis. J Gastroenterol Hepatol, 2010, 25(11): 1718-1725 PMID: 21039832

[36] LindorRA, LindorKD. The value of observational research in liver diseases. Hepatology, 2011, 53(1): 1-3 PMID: 21254155